ICPT

Ocaliva

Primary Sclerosing Cholangitis

Stage (next event)

Expected Date

TBD

Catalyst Info & Data Links

TITLE: Ocaliva in Primary Sclerosing Cholangitis 

  • ClinicalTrial.gov (NCT02177136) Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC) (AESOP)

  • Learn more


WHAT IS THE NEXT CATALYST EVENT?

  • TBD


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBD


PRIOR DATA


PRESS RELEASES

POSTERS


PRESENTATIONS


PUBLICATIONS


MECHANISM OF ACTION / RATIONALE

  • Obeticholic acid is an agonist for FXR, a nuclear receptor expressed in the liver and intestine. FXR is a key regulator of bile acid, inflammatory, fibrotic, and metabolic pathways. FXR activation decreases the intracellular hepatocyte concentrations of bile acids by suppressing de novo synthesis from cholesterol as well as by increased transport of bile acids out of the hepatocytes. These mechanisms limit the overall size of the circulating bile acid pool while promoting choleresis, thus reducing hepatic exposure to bile acids.


  • Source - FDA Label (section 12.1)

COMPETITORS

MARKET

  • 20.9 cases of PSC per 100,000 in men

  • 6.3 per 100,000 in women

  • Data from Olmsted County (USA) in the year 2000

  • Source

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

ICPT Ocaliva Phase 3 Readout

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon